Biotech Values

[bladerunner1717]

rkw,

I'm wondering what are reasonable expectations on a deal for a drug like 534. Lets assume, for argument's sake, that the drug could move to first-line therapy for CML and be used in solid tumor indications. So potentially, we're talking about a $3-4 billion/year drug here. Could we be looking at an Erbitux/BMY kind of deal? (Imclone had a six billion market cap, as I recall, before Erbitux was ever approved.)

What kind of deal do you think Berger wants, assuming he gets 534 into pivotals before signing a deal? The Erbitux/BMY may be an unrealistic prototype, but what is realistic, in your opinion?


Bladerunner